Lakefront Biotherapeutics NV (GXE.DE)
XETRA · EUR · Healthcare · Biotechnology
€28.16 (-0.42%) as of
Key statistics
- Market cap
- 1.86B
- P/E (TTM)
- 3.11
- EPS (TTM)
- 9.06
- Dividend yield
- 0.00%
- 52-week range
- 22.84 – 44.47
- Beta
- 0.06
- Revenue (TTM)
- 990.57M
- Profit margin
- 60.23%
- Volume
- 569.00
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mechelen, Belgium
- Employees
- 196
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.